PharmaCyte Biotech (NASDAQ:PMCB) Releases Quarterly Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) posted its quarterly earnings data on Friday. The company reported ($0.29) earnings per share for the quarter, Zacks reports.

PharmaCyte Biotech Stock Performance

PMCB stock opened at $1.72 on Friday. The stock has a market capitalization of $13.21 million, a PE ratio of 2.61 and a beta of -0.21. The company has a fifty day moving average of $1.75 and a 200-day moving average of $1.86. PharmaCyte Biotech has a one year low of $1.39 and a one year high of $2.58.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.